Risperidone in pervasive developmental disorders

References

• Campbell M, Anderson LT, Meier M et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J. Am. Acad. Child Psychiatry 17, 640–655 (1978).
   PubMedGoogle Scholar
• Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry 36, 835–843 (1997).
   PubMed Web of Science ®Google Scholar
• Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT. Behavioral effects of haloperidol in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry 19, 665–677 (1980).
   Web of Science ®Google Scholar
• Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J. Autism. Dev. Disord. 19, 227–239 (1989).
   PubMed Web of Science ®Google Scholar
• Volkmar F, Cook EH, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J. Am. Acad. Child Adolesc. Psychiatry 38(Suppl. 12), S32–S54 (1999).
   PubMed Web of Science ®Google Scholar
• Aman MG, Lam KS, Van Dourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J. Child Adolesc. Psychopharmacol. 15(1), 116–126 (2005).
   PubMed Web of Science ®Google Scholar
• Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Psychopharmacology. In: Autism and Pervasive Developmental Disorders (Second Edition). Volkmar FR (Ed.). Cambridge University Press, Cambridge, UK (2005) (In Press).
   Google Scholar
• Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol. Bull. 33(1), 155–159 (1997).
   PubMed Web of Science ®Google Scholar
• Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J. Autism Dev. Disord. 27(3), 313–323 (1997).
   PubMed Web of Science ®Google Scholar
• Perry R, Pataki C, Munox-Silva DM, Armenteros J, Silva RR. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J. Child Adolesc. Psychopharmacol. 7(3), 167–179 (1997).
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Holmes JP, Bronson MR et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J. Am. Acad. Child Adolesc. Psychiatry 36(5), 685–693 (1997).
   PubMed Web of Science ®Google Scholar
• Zuddas A, DiMartino A, Muglia P, Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J. Child Adolesc. Psychopharmacol. 10(2), 79–90 (2000).
   PubMed Web of Science ®Google Scholar
• Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J. Am. Acad. Child Adolesc. Psychiatry 41(2), 140–147 (2002).
   PubMed Web of Science ®Google Scholar
• Nicolson R, Awad G, Sloman L. An open label trial of risperidone in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry 37(4), 372–376 (1998).
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorder. J. Am. Acad. Child Adolesc. Psychiatry 40(10), 1206–1214 (2001).
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J. Clin. Psychiatry 64(9), 1039–1047 (2003).
   PubMed Web of Science ®Google Scholar
• Gagliano A, Germano E, Pustorino G et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J. Child Adolesc. Psychopharmacol. 14(1), 39–47 (2004).
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry 55, 633–641 (1998).
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioral problems. N. Engl J. Med. 347(5), 314–321 (2002).
   PubMed Web of Science ®Google Scholar
• Arnold LE, Vitiello B, McDougle CJ et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J. Am. Acad. Child Adolesc. Psychiatry 42(12), 1443–1450 (2003).
   PubMed Web of Science ®Google Scholar
• Research Units of Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry 162(7), 1361–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5), e634–e641 (2005).
   Google Scholar
• Martin A, Scahill L, Anderson GM et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am. J. Psychiatry 161(6), 1125–1127 (2004).
   PubMed Web of Science ®Google Scholar
• Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J. Child Adolesc. Psychopharmacol. 11(3), 229–238 (2001).
   PubMed Web of Science ®Google Scholar
• Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr. Drugs 6(1), 33–44 (2004).
   PubMedGoogle Scholar
• Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J. Child Adolesc. Psychopharmacol. 11(4), 389–394 (2001).
   PubMed Web of Science ®Google Scholar
• Kwon H. Tardive dyskinesia in an autistic patient treated with risperidone. Am. J. Psychiatry 161(4), 757–758 (2004).
   PubMed Web of Science ®Google Scholar
• Posey DJ, Walsh KH, Wilson GA, McDougle CJ. Risperidone in the treatment of two very young children with autism. J. Child Adolesc. Psychopharmacol. 9(4), 273–276 (1999).
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Scahill L, Aman MG et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry 162(6), 1142–1148 (2005).
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology (Revised Edition). DHHS Publication No. ADM 91–338. US Department of Health, Education, and Welfare, DC, USA, (1976).
   Google Scholar